Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Approximately 40% of lung cancer patients present with advanced disease at diagnosis. To date, there is a lack of literature on the effectiveness of local therapies, such as stereotactic radiotherapy and thermal ablation, in treating primary lung cancer.
To characterize the mutational landscape of our cohort and its association with clinical response, we performed whole exome DNA sequencing analysis of pre-treatment formalin-fixed paraffin-embedded (FFPE) NSCLC samples from 49 patients treated with immune checkpoint blockers. The mean target coverage was 206.3× and 97.08% of nucleotides read at least 20×. The average somatic mutation load was 633.27 (range 10–6926) with a median of 346.
ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)–naive, advanced anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) S. Popat1, M. Tiseo2, S. Gettinger3, S. Peters4, J. Haney5, D.
Background: BRG, an investigational oral ALK inhibitor with preclinical activity against ALK mutants resistant to crizotinib (CRZ) and other ALK inhibitors, was studied in pts with advanced malignancies, including ALK+ NSCLC. Methods: 137 pts (ALK+ NSCLC, n = 79) received oral BRG (30–300 mg/d) in an ongoing phase 1/2, single-arm, open-label, multicenter trial (NCT01449461). We report activity by RECIST v1.1 (in ALK+ NSCLC pts) and safety (in all pts).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
